TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07896252: Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Admin

Sponsor: AeroRx Therapeutics Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 64 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,466,000

Rescue Site Savings

+$5,577,600

Unlock Full NCT07896252 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07896252 Rescue Dossier →